191 related articles for article (PubMed ID: 35468619)
21. Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia.
Sakthivel D; Brown-Suedel AN; Keane F; Huang S; Sherry KM; Charendoff CI; Dunne KP; Robichaux DJ; Le B; Shin CS; Carisey AF; Flanagan JM; Bouchier-Hayes L
bioRxiv; 2023 May; ():. PubMed ID: 37398413
[TBL] [Abstract][Full Text] [Related]
22. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
[TBL] [Abstract][Full Text] [Related]
23. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
[TBL] [Abstract][Full Text] [Related]
24. Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia?
Florio D; Marasco D
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255885
[TBL] [Abstract][Full Text] [Related]
25. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
Wang GG; Pasillas MP; Kamps MP
Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
[TBL] [Abstract][Full Text] [Related]
26. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
[TBL] [Abstract][Full Text] [Related]
27. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
28. Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
Martelli MP; Rossi R; Venanzi A; Meggendorfer M; Perriello VM; Martino G; Spinelli O; Ciurnelli R; Varasano E; Brunetti L; Ascani S; Quadalti C; Cardinali V; Mezzasoma F; Gionfriddo I; Milano F; Pacini R; Tabarrini A; Bigerna B; Albano F; Specchia G; Vetro C; Di Raimondo F; Annibali O; Avvisati G; Rambaldi A; Falzetti F; Tiacci E; Sportoletti P; Haferlach T; Haferlach C; Falini B
Blood; 2021 Dec; 138(25):2696-2701. PubMed ID: 34343258
[TBL] [Abstract][Full Text] [Related]
29. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
30. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
31. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
32. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
[TBL] [Abstract][Full Text] [Related]
33. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
Vascotto C; Lirussi L; Poletto M; Tiribelli M; Damiani D; Fabbro D; Damante G; Demple B; Colombo E; Tell G
Oncogene; 2014 May; 33(22):2876-87. PubMed ID: 23831574
[TBL] [Abstract][Full Text] [Related]
34. C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.
Collins C; Wang J; Miao H; Bronstein J; Nawer H; Xu T; Figueroa M; Muntean AG; Hess JL
Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9899-904. PubMed ID: 24958854
[TBL] [Abstract][Full Text] [Related]
35. miRNA-mRNA Profiling Reveals Prognostic Impact of
Gadewal N; Kumar R; Aher S; Gardane A; Gaur T; Varma AK; Khattry N; Hasan SK
Oncol Res; 2020 May; 28(3):321-330. PubMed ID: 32059753
[TBL] [Abstract][Full Text] [Related]
36. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.
Lawrence HJ; Rozenfeld S; Cruz C; Matsukuma K; Kwong A; Kömüves L; Buchberg AM; Largman C
Leukemia; 1999 Dec; 13(12):1993-9. PubMed ID: 10602420
[TBL] [Abstract][Full Text] [Related]
37. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
[TBL] [Abstract][Full Text] [Related]
38. An atypical GABARAP binding module drives the pro-autophagic potential of the AML-associated NPM1c variant.
Mende H; Khatri A; Lange C; Poveda-Cuevas SA; Tascher G; Covarrubias-Pinto A; Löhr F; Koschade SE; Dikic I; Münch C; Bremm A; Brunetti L; Brandts CH; Uckelmann H; Dötsch V; Rogov VV; Bhaskara RM; Müller S
Cell Rep; 2023 Dec; 42(12):113484. PubMed ID: 37999976
[TBL] [Abstract][Full Text] [Related]
39. The Historical Relationship Between Meis1 and Leukemia.
Meriç N; Kocabaş F
Adv Exp Med Biol; 2022; 1387():127-144. PubMed ID: 35304708
[TBL] [Abstract][Full Text] [Related]
40. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
